Sareum Holdings Plc – Product Pipeline Review

Global Markets Direct’s, ‘Sareum Holdings Plc – Product Pipeline Review – 2016’, provides an overview of the Sareum Holdings Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sareum Holdings Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sareum Holdings Plc

The report provides overview of Sareum Holdings Plc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sareum Holdings Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sareum Holdings Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sareum Holdings Plc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sareum Holdings Plc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sareum Holdings Plc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Sareum Holdings Plc Snapshot 6

Sareum Holdings Plc Overview 6

Key Facts 6

Sareum Holdings Plc - Research and Development Overview 7

Key Therapeutic Areas 7

Sareum Holdings Plc - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Sareum Holdings Plc - Pipeline Products Glance 14

Sareum Holdings Plc - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Sareum Holdings Plc - Drug Profiles 16

CCT-244747 - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

SAR-020106 - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

SAR-20347 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

SAR-3 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

SAR-4 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

SART-1 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

SART-29 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

SART-33 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Sareum Holdings Plc - Pipeline Analysis 28

Sareum Holdings Plc - Pipeline Products by Target 28

Sareum Holdings Plc - Pipeline Products by Route of Administration 29

Sareum Holdings Plc - Pipeline Products by Molecule Type 30

Sareum Holdings Plc - Pipeline Products by Mechanism of Action 31

Sareum Holdings Plc - Dormant Projects 32

Sareum Holdings Plc - Company Statement 33

Sareum Holdings Plc - Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

List of Tables

Sareum Holdings Plc, Key Facts 6

Sareum Holdings Plc – Pipeline by Indication, 2016 8

Sareum Holdings Plc – Pipeline by Stage of Development, 2016 10

Sareum Holdings Plc – Monotherapy Products in Pipeline, 2016 11

Sareum Holdings Plc – Out-Licensed Products in Pipeline, 2016 12

Sareum Holdings Plc – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Sareum Holdings Plc – Preclinical, 2016 14

Sareum Holdings Plc – Discovery, 2016 15

Sareum Holdings Plc – Pipeline by Target, 2016 28

Sareum Holdings Plc – Pipeline by Route of Administration, 2016 29

Sareum Holdings Plc – Pipeline by Molecule Type, 2016 30

Sareum Holdings Plc – Pipeline Products by Mechanism of Action, 2016 31

Sareum Holdings Plc – Dormant Developmental Projects,2016 32

Sareum Holdings Plc, Subsidiaries 35

List of Figures

List of Figures

Sareum Holdings Plc – Pipeline by Top 10 Indication, 2016 8

Sareum Holdings Plc – Pipeline by Stage of Development, 2016 10

Sareum Holdings Plc – Monotherapy Products in Pipeline, 2016 11

Sareum Holdings Plc – Pipeline by Target, 2016 28

Sareum Holdings Plc – Pipeline by Route of Administration, 2016 29

Sareum Holdings Plc – Pipeline by Molecule Type, 2016 30

Sareum Holdings Plc – Pipeline Products by Mechanism of Action, 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports